PH 50

Drug Profile

PH 50

Alternative Names: N-1177; PH-50

Latest Information Update: 08 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Corporation; IMCOR Pharmaceutical
  • Class Iodinated contrast media
  • Mechanism of Action Emission-computed tomography enhancers; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer metastases; Coronary artery disease

Most Recent Events

  • 14 May 2007 Discontinued - Phase-I for Cancer metastases diagnosis in USA (IV)
  • 05 Feb 2004 Photogen Technologies is now called IMCOR Pharmaceutical
  • 02 Apr 2001 Phase-I clinical trials for Cancer metastases diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top